All In Biotech

Drug Trial Radar · NCT07947043

Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection

An Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of Autologous Tumor-Infiltrating Lymphocyte (TIL) Infusion for the Treatment of Recurrent/Metastatic Lung Cancer or Cervical Cancer in Previously Treated Patients.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Dec 2027

Study completion Dec 2029

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu Dekang Biotechnology Co., Ltd
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single - center, single - arm, open - label, single - dose, dose - escalation exploratory study. The main purpose is to evaluate the safety and tolerability of autologous tumor - infiltrating lymphocyte injection in the treatment of recurrent or metastatic lung cancer or cervical cancer. Meanwhile, it will also preliminarily explore the effectiveness, PK characteristics, PD characteristics and changes in immune - related parameters of autologous tumor - infiltrating lymphocyte injection in subjects with recurrent or metastatic lung cancer or cervical cancer.

Conditions

  • Recurrent or Metastatic Lung Cancer or Cervical Cancer

Interventions

  • Autologous Tumor-Infiltrating Lymphocyte InjectionBiological

    DK008

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Up to 12 months after first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.